Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialLAVALLE-GONZALEZ, F. J; JANUSZEWICZ, A; DAVIDSON, J et al.Diabetologia (Berlin). 2013, Vol 56, Num 12, pp 2582-2592, issn 0012-186X, 11 p.Article

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesNYIRJESY, Paul; SOBEL, Jack D; FUNG, Albert et al.Current medical research and opinion. 2014, Vol 30, Num 6, pp 1109-1119, issn 0300-7995, 11 p.Article

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy ParticipantsDEVINENI, Damayanthi; VACCARO, Nicole; POLIDORI, David et al.Clinical therapeutics. 2014, Vol 36, Num 5, pp 698-710, issn 0149-2918, 13 p.Article